Pictet Emerging Markets Rising Economies ETF RISE
17.28 USD -0.13 (-0.73%)
Nov 3, 2026, 11:44 AM EST
17.28 Day range 17.31
17.27 52-week range 19.66
- YTD
- -10.92%
- 1 year
- -10.92%
- Market cap
- 97.23M
- EPS (ttm)
- 1.73
- P/E ratio
- 10.00
- YTD return
- -10.92%
- 1-year return
- -10.92%
- Volume
- 439
- Avg volume
- 2.59K
- Open
- 17.31
- Previous close
- 17.41
- Day's range
- 17.28 – 17.31
- 52-week range
- 17.27 – 19.66
2Y -1.99 (-10.26%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 19.95
- 200-day average
- 20.11
About Pictet Emerging Markets Rising Economies ETF
The investment seeks to profit from rising interest rates by tracking the performance of a portfolio consisting of exchange traded futures contracts and options on futures on 2, 5 and 10-year U.S. Treasury securities weighted to achieve a targeted negative 10 year average effective portfolio duration. The weighting of the Treasury Instruments constituting the Benchmark Component Instruments will be based on each maturity's duration contribution. The expected range for the duration weighted percentage of the 2 year and 5 year maturity Treasury Instruments will be from 30% to 70%.
News
Green Thumb Industries Enters Polk County with Its 27th Florida Location, RISE Dispensary Mulberry
The Real Brokerage to Bring the Future of Real Estate to Life at RISE 2026
Double-Digit Returns, Single-Minded Focus: Revisiting Your Emerging Markets ETF
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
Green Thumb Opens Its 24th Florida Location, RISE Dispensary Port St. Lucie, on August 22
Green Thumb Opens Its 13th Nevada Location, RISE Dispensary Sparks, on August 18
Green Thumb Opens Its 23rd Florida Location, RISE Dispensary Port Charlotte, on August 10
Green Thumb Expands Pennsylvania Retail Footprint with the Opening of RISE Dispensary Hanover
Crawford & Company® Renews Its Commitment to RISE®
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Your note
Sign in to keep a note on RISE — it syncs with the Stock Master app.
